San Francisco, June 06, 2025 - 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company, has announced the approval of non-qualified stock options for three new employees. This decision, made by the Compensation Committee of the Company's Board of Directors, involves the issuance of options to purchase a total of 61,100 shares of 89bio's common stock. These inducement grants, effective June 3, 2025, are part of the 2023 Inducement Plan and align with Nasdaq Listing Rule 5635(c)(4). The exercise price for these options corresponds to the closing price on the grant date, and the options will vest over four years, with 25% vesting at the end of the first year and the remainder vesting quarterly, contingent upon continued employment.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。